Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis

Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.

ALXN : 114.51 (+2.48%)
ALNY : 133.64 (+2.08%)
IONS : 50.77 (+1.14%)
AKCA : 18.14 (unch)
Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALNY : 133.64 (+2.08%)
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable

--- New Clinical Data Presented at the European Society of Cardiology 2020 Congress Provide Further Evidence that Treatment with Patisiran may Lead to Substantial Reduction in Cardiac Amyloid Burden in...

ALNY : 133.64 (+2.08%)
Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

MS : 47.63 (-1.51%)
ALNY : 133.64 (+2.08%)
Alnylam's Share Price Rises YTD on Pipeline Developments

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

ALNY : 133.64 (+2.08%)
EBS : 100.75 (+0.75%)
HZNP : 78.16 (-0.86%)
ALIM : 5.24 (-5.42%)
Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease

Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies' previously announced...

BX : 51.30 (-0.83%)
ALNY : 133.64 (+2.08%)
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance

Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.

REGN : 571.51 (+2.85%)
ALNY : 133.64 (+2.08%)
NVS : 88.92 (-0.65%)
VIR : 32.89 (+2.78%)
Look for Shares of Alnylam Pharmace to Potentially Rebound after Yesterday's 4.64% Sell Off

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $142.49 to a high of $149.21. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of...

ALNY : 133.64 (+2.08%)
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 12.85% and 5.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 133.64 (+2.08%)
Alnylam: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $179.2 million in its second quarter.

ALNY : 133.64 (+2.08%)
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity

--a^' Achieved Second Quarter 2020 GIVLAARI(R) Global Net Product Revenues of $11.0 Million with More Than 100 Patients on Commercial Product Worldwide -

ALNY : 133.64 (+2.08%)
Alnylam Announces Planned Transition of Barry Greene, President

--- Yvonne Greenstreet to be Named President and Chief Operating Officer; Company Initiates Search for a Chief Commercial Officer -

ALNY : 133.64 (+2.08%)
Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and...

ALNY : 133.64 (+2.08%)
Alnylam Pharmace Rises 1.50% on Heavy Volume: Watch For Potential Pullback

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $152.61 to a high of $156.30. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

ALNY : 133.64 (+2.08%)
New GERM ETF Launched to Tap the Growing Biotech Sector

GERM invests in the hottest emerging biotechnology trends.

MRNA : 68.72 (-0.78%)
ALNY : 133.64 (+2.08%)
BIO : 515.68 (-0.43%)
SBIO : 41.14 (+0.78%)
PBE : 56.68 (+0.98%)
ARKG : 62.57 (+1.71%)
NASDAQ Higher for Fifth Straight Day as Stocks Rally in Final Hour

NASDAQ Higher for Fifth Straight Day as Stocks Rally in Final Hour

SPOT : 241.01 (+0.70%)
TDOC : 215.28 (+6.23%)
UNFI : 17.23 (+1.35%)
ZS : 137.99 (+2.27%)
ACMR : 69.88 (-3.19%)
ESTC : 108.28 (-0.16%)
CRUS : 61.06 (+0.91%)
EVOP : 24.52 (-0.16%)
CMC : 19.59 (-0.91%)
SCHN : 19.44 (-0.21%)
CVET : 21.32 (+0.95%)
XOM : 35.53 (-2.47%)
UNG : 11.67 (-4.19%)
WEAT : 5.57 (+0.36%)
FVRR : 133.07 (+5.18%)
SPTN : 16.99 (-1.91%)
DSPG : 12.95 (-0.99%)
ALNY : 133.64 (+2.08%)
AVXL : 4.06 (-0.73%)
EDIT : 32.76 (+1.30%)
Alnylam to Host Seventh Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7th annual series of "RNAi Roundtable" webinars over the coming weeks. The...

ALNY : 133.64 (+2.08%)
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma...

ALNY : 133.64 (+2.08%)
Watch for Alnylam Pharmace to Potentially Pullback After Gaining 2.32% Yesterday

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $132.88 to a high of $136.22. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high...

ALNY : 133.64 (+2.08%)
Alnylam???s Share Price Rises YTD on Pipeline Developments

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

ALNY : 133.64 (+2.08%)
AKCA : 18.14 (unch)
AYTU : 1.3000 (unch)
AXLA : 4.70 (+0.86%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar